PFIZ34 Stock Price and Chart — BMFBOVESPA:PFIZ34

Overview

Financials News Ideas Discussions Technicals Seasonals Bonds

Key facts today

Pfizer's COVID-19 vaccine for the KP.2 subvariant has been approved by the UK Medicines and Healthcare products Regulatory Agency for adults, following recognition from the European Medicines Agency.

Morgan Stanley cut its price target on Pfizer, Inc. (PFE) from $31 to $30. Analysts have an average outperform rating, with price targets ranging from $27 to $45.

Pfizer Inc is involved in the development of new obesity drugs, participating alongside other major players in the competitive landscape of the obesity treatment market.

Analyze the impact Analyze the impact

About Pfizer

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Financials

Performance

Revenue to profit conversion

Debt level and coverage

Earnings

Next:—

‪0.00‬

Ideas

See all ideas

Technicals

Summarizing what the indicators are suggesting.

Oscillators

Neutral

SellBuy

Strong sellStrong buy